Wilson L - Search Results

1

Clinical and Economic Burden of Valley Fever in Arizona: An Incidence-Based Cost-of-Illness Analysis.

Grizzle AJ, Wilson L, Nix DE, Galgiani JN. Grizzle AJ, et al. Among authors: wilson l. Open Forum Infect Dis. 2020 Dec 28;8(2):ofaa623. doi: 10.1093/ofid/ofaa623. eCollection 2021 Feb. Open Forum Infect Dis. 2020. PMID: 33575419 Free PMC article.

2

Cost-of-illness of scleroderma: the case for rare diseases.

Wilson L. Wilson L. Semin Arthritis Rheum. 1997 Oct;27(2):73-84. doi: 10.1016/s0049-0172(97)80008-x. Semin Arthritis Rheum. 1997. PMID: 9355206

3

Longitudinal assessment of economic burden and clinical outcomes in acromegaly.

Wilson LS, Shin JL, Ezzat S. Wilson LS, et al. Endocr Pract. 2001 May-Jun;7(3):170-80. doi: 10.4158/EP.7.3.170. Endocr Pract. 2001. PMID: 11421563

4

The Rise of Valley Fever: Prevalence and Cost Burden of Coccidioidomycosis Infection in California.

Wilson L, Ting J, Lin H, Shah R, MacLean M, Peterson MW, Stockamp N, Libke R, Brown P. Wilson L, et al. Int J Environ Res Public Health. 2019 Mar 28;16(7):1113. doi: 10.3390/ijerph16071113. Int J Environ Res Public Health. 2019. PMID: 30925716 Free PMC article.

5

The opioid public health crisis in Texas: Characterizing real-world healthcare resource utilization and economic burden in different clinical settings.

Zhong L, Smith ML, Lyu N, Davlasheridze M, Alonzo J, Lee S, Wilson L, Ory MG. Zhong L, et al. Among authors: wilson l. J Opioid Manag. 2024 Sep-Oct;20(5):393-409. doi: 10.5055/jom.0899. J Opioid Manag. 2024. PMID: 39545444

6

Annual direct cost of urinary incontinence.

Wilson L, Brown JS, Shin GP, Luc KO, Subak LL. Wilson L, et al. Obstet Gynecol. 2001 Sep;98(3):398-406. doi: 10.1016/s0029-7844(01)01464-8. Obstet Gynecol. 2001. PMID: 11530119

7

The direct cost and incidence of systemic fungal infections.

Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J. Wilson LS, et al. Value Health. 2002 Jan-Feb;5(1):26-34. doi: 10.1046/j.1524-4733.2002.51108.x. Value Health. 2002. PMID: 11873380 Free article.

8

Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.

Wilson L, Huang W, Chen L, Ting J, Cao V. Wilson L, et al. Thyroid. 2017 Aug;27(8):1043-1052. doi: 10.1089/thy.2016.0572. Epub 2017 Jun 7. Thyroid. 2017. PMID: 28486081

9

A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma.

Chan A, Dang C, Wisniewski J, Weng X, Hynson E, Zhong L, Wilson L. Chan A, et al. Among authors: wilson l. Am J Clin Oncol. 2022 Feb 1;45(2):66-73. doi: 10.1097/COC.0000000000000884. Am J Clin Oncol. 2022. PMID: 34991104

10

Cumulative cost pattern comparison of prostate cancer treatments.

Wilson LS, Tesoro R, Elkin EP, Sadetsky N, Broering JM, Latini DM, DuChane J, Mody RR, Carroll PR. Wilson LS, et al. Cancer. 2007 Feb 1;109(3):518-27. doi: 10.1002/cncr.22433. Cancer. 2007. PMID: 17186528 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,108 results

Search Page

Filters